Dr. Ruotolo has worked in the area of lipoprotein metabolism and atherosclerosis in humans for 30 years, and has co-authored numerous original publications, including reviews and book chapters.

Dr. Ruotolo received his MD from the University of Napoli (Italy), and board certification in Diabetes and Metabolism from the University of Milano (Italy). He also holds a PhD in Clinical Pathophysiology from the Italian Ministry of University and Scientific Research (MIUR).

Dr. Ruotolo currently works as Medical Fellow in Cardiovascular Research at Eli Lilly & Company (Indianapolis, IN). Prior to this appointment, he has worked as Cardiovascular Translational Leader at AstraZeneca (Molndal, Sweden). Previously, Dr. Ruotolo served as the Head of the Lipid Clinic and the Cardiovascular Prevention Clinic, as well as of the Lipoprotein and Atherosclerosis Research Unit at San Raffaele Institute (Milano, Italy). He has also been Scientific Director of Penn Medical Laboratory at MedStar Research Institute (Washington, DC), and Visiting Scientist at the Atherosclerosis Research Unit, Karolinska Institute (Stockholm, Sweden).

Dr. Ruotolo is a Fellow of the American Heart Association (FAHA), European Society of Cardiology (FESC) and National Lipid Association (FNLA). Dr. Ruotolo is in the Editorial Board of the Journal of Clinical Lipidology. Dr. Ruotolo has been Principal Investigator for the NHLBI-funded Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) Study and for the Cremona Study, and served on the Steering Committee of the Strong Heart Study and Stop Atherosclerosis in Native Diabetics Study (SANDS).